Pascal immune to corneal biomechanics

Article

Intraocular pressure (IOP) measurements with the Pascal dynamic contour tonometer (PDCT) are relatively immune to changes in corneal biomechanics and pachymetry.

Intraocular pressure (IOP) measurements with the Pascal dynamic contour tonometer (PDCT) are relatively immune to changes in corneal biomechanics and pachymetry, according to a study published in the January issue of the American Journal of Ophthalmology.

Dr Jay Pepose and colleagues from the Pepose Vision Institute and the Washington University School of Medicine, St Louis, USA, conducted a prospective, non-randomized study to compare the preoperative and postoperative measurements of corneal biomechanical properties and IOP using Goldmann applanation tonometry (GAT), the ocular response analyser (ORA) and the PDCT in eyes undergoing myopic LASIK.

A total of 66 myopic eyes were measured for IOP before and after LASIK using the three devices in a randomized sequence. Metrics of corneal biomechanical properties were also recorded. After LASIK, there was a reduction in mean corneal pachymetry of 90.2 µm and in IOP measurements with GAT (Delta= -1.8±-2.8 mmHg; p<0.01), ORA-Goldmann (Delta= -4.6±-2.8 mmHg; p<0.01) and ORA-corneal compensated (Delta= -2.1±-2.6 mmHg; p<0.05). There was, however, no statistically significant difference between pre- and postoperative IOP measurements taken by PDCT (Delta= -0.5±-2.6 mmHg).

It was concluded that IOP measurements with PDCT are less likely to be affected by changes in corneal biomechanics and pachymetry after LASIK than if they are taken by GAT or ORA.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.